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Conclusion: The combination of nonspecific clinical signs
(pain, dyspepsia) with biochemical markers of biliary pathology
and endocrine pancreatic insufficiency – of PCa patients demon-
strates the obligatoriness of differential diagnostic pancreatic and
biliary pathology in their earlier stages.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.027
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Acute myelomonocytic leukemia (FAB M4) is one of the most
common forms of acute myeloid leukemia (AML). This AML form
is characterized by rapid accumulation transformed myeloblasts
and monoblasts in bone marrow, with the rapid suppression of
normal hematopoiesis. Bone marrow microenvironment is one
of the main factors determining drug resistance of leukemic cells.
It is known that the adhesion of leukemic cells to mesenchymal
stem cell and bone marrow extracellular matrix (laminin,
collagen) enhances their drug resistance. However, it remains
unknown whether the emergence of drug resistance when
cell–cell contacts are formed only between leukemia cells,
without the involvement of bone marrow stromal elements. We
studied the role of cell aggregation in drug resistance of leukemic
cells. We used the bone marrow mononuclear cells (BMMC)
isolated from the patients with acute myelomonocytic leukemia.
For the formation of multicellular aggregates, BMMC were
cultivated in 96-well plates coated with 1.5% agarose. We showed
that resistance of BMMC to bortezomib, doxorubicin and
fludarabine in multicellular aggregates was increased. In three-
dimensional multicellular aggregates of BMMC index IC50 for
bortezomib, doxorubicin and fludarabine was 7 ± 1 ng/ml,
1 ± 0.4 mkM and 0.8 ± 0.05 mkM, respectively. In control condi-
tion, index IC50 bortezomib, doxorubicin and fludarabine was
significantly lower, 2 ± 0.5 ng/ml, 0.3 ± 0.05 mkM and 0.07 ±
0.001 mkM, respectively. In multicellular aggregates of BMMC
number of mitotic cells and expression of Ki-67 protein were
not significantly different from the control. It has also been
shown that cells in multicellular aggregates increased expression
antiapoptotic protein Bcl-2. Suppression of BMMC aggregation by
culturing the cells in medium containing 0.9% methylcellulose
resulted in decreased IC50 index for bortezomib, doxorubicin
and fludarabine, 2 ± 0.7 ng/ml, 0.12 ± 0.004 mkM and 0.04
± 0.005 mkM, respectively. Expression of the Bcl-2 protein was
also decreased. This work demonstrates the involvement of cell
aggregation in the formation of drug resistance phenotype in
leukemic cells.
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Blood-derived biomarkers, such as circulating tumour cells
(CTCs) and circulating tumour DNA (ctDNA), are a valuable source
of molecular genetic data for tumours they spring from. In trans-
lational cancer research, the ‘‘liquid biopsy” concept has been put
forward to denote the detection and molecular characterization
of these biomarkers.
The idea of liquid biopsy is based on a hypothesis that profiles
of somatic mutations in CTCs and ctDNA are identical to those in
the original tumour. Therefore, the mutation status of the source
tumour can be revealed through the molecular analysis of the
CTCs and ctDNA obtained from the blood. The major advantages
of liquid biopsy are an essentially decreased invasiveness (no
need for tissue biopsy, surgery or bronchoscopy) and an ability
to carry out the analysis at patient’s follow up (e.g. to monitor
for residual disease).
However, both the CTCs and ctDNA are not abundant in the
bloodstream and their capture is technically challenging. Also,
due to tumour heterogeneity, the CTCs may not fully represent
the entire tumour, while ctDNA is naturally fragmented and
degraded, so its utility for genetic analysis may be limited. Finally,
the DNA extracted from CTCs and, especially, ctDNA are ‘‘con-
taminated” by DNA from non-tumour cells from the bloodstream
raising a challenge of detecting mutant DNA among significantly
prevailing wild-type DNA.
Some of these issues can be overcome by using such advanced
techniques as BEAMing, digital PCR or ultra-deep sequencing, but
their use in standard clinical settings is limited by the need for
special equipment and associated costs. Inexpensive and less
sophisticated, but still highly sensitive and specific, approaches,
such as COLD-PCR or wild-type blocking PCR, are also available
to detect ‘‘druggable” mutations in CTCs and ctDNA.
Application of these approaches of liquid biopsy in clinical
practice may be highly beneficial for personalized care of lung
cancer patients.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.029
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Background: The research for procathepsin B and endogenous
inhibitors of cysteine proteases in tumor markers of human
reproductive system is important for early diagnostics of cancer.
Preform of cathepsin B and cystatins B and C also are universally
involved into development of different tumors. Tumor cells as
well as tumor-associated macrophages have been shown to
secrete active forms of proteases and their inhibitors; however,
their roles, especially those of proenzymes as markers of
malignancy, are still under investigation.
Aim: to evaluate procathepsin B and endogenous inhibitors of
cysteine proteases cystatins B and C in tumors of reproductive
system.
Materials and methods: Serum and ascites fluid of 38 patients
with ovarian cancer (among them 15 patients after treatment)
and benign ovarian tumors (n = 9), endometrial cancer (n = 31,
before treatment 14), mammalian cancer (n = 29, before treat-
ment 18) of stages II–IV for all groups, from Department of Gyne-
cology of Regional Oncology Center, Novosibirsk, were under
investigation. Serum of practically healthy women aged 18–80
(n = 82) from Regional Diagnostic Center, Novosibirsk, was used
as a control group. Serum of women with tumors of the reproduc-
tive system and ascites fluids of women with ovarian tumors
(aged 18–80 years), before operation were used for assay of pro-
cathepsin B, cysteine protease inhibitors cystatins B and C. Serum
procathepsin B concentration was measured by ELISA commer-
cial kit for human (R&D) USA; cystatin C using BioVendor com-
mercial kits (Czechia), cystatin B – with help of ELISA kits for
human (USCN Life Science Inc., Wuhan, China). Common biomar-
ker of ovarian cancer, CA-125, was assayed by using a commercial
kit (Vector, Koltsovo, Novosibirsk Region, Russia). Statistical anal-
ysis performed by one a way ANOVA Statistic 12, program with
help of Kruskall–Wallis test and the Mann–Whitney U test used
to assess differences in procathepsin B or cystatins B and C levels
between patient groups. Statistical analysis was performed with
the soft package Statistics 12, with the level of significance being
set at <0.05.
Results: In serum of patients with endometrial cancer, ovarian
cancer, mammalian cancer – significant increases in serum pro-
cathepsin B (p < 0.001), cystatin B (p < 0.05) and CA-125
(p < 0.001) were noted. However, in patients with benign tumor
increased serum common tumor marker CA-125 (p = 0.005 vs.
healthy controls) was shown without any changes in serum level
of procathepsin B, cystatins B and C. Concentrations procathepsin
B and Cystatin B in serum and ascites of patients with ovarian
tumor was used to assess differences in procathepsin B or cys-
tatins B and C levels between groups. Serum procathepsin B
(p < 0.05) and in ascites fluid of patients with ovarian cancer
(p < 0.001) was shown to significant increase in ovarian cancer
group vs. benign ovarian tumors group. The concentration of
CA-125 in ascites of patients with ovarian cancer (p < 0.000) and
benign ovarian tumors (p < 0.05) was high, but has not differences
between them (p > 0.1).
Conclusion: One can conclude that serum procathepsin B and
endogenous inhibitors of cysteine proteases cystatin B are
prospective tumor biomarkers in reproductive system tumors.
Procathepsin B and cystatin B seem to be important in differential
diagnosis of ovarian cancer and benign ovarian tumors. Pro-
cathepsin B and cystatin B are involved in breast and endometrial
cancer that warrants further investigation of their role in cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.030
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Tumor-associated neutrophils (TANs) are the cell population
that differs in morphofunctional characteristics from peripheral
blood cells (Gregory and Houghton, 2011). The first study to iden-
tify the presence of TANs as an independent poor prognostic fac-
tor and to include TANs into a prognostic risk model was
published in 2006 (Donskov , 2006). Specific signals during cancer
progression have been shown to induce the emergence of a pro-
tumor phenotype of neutrophils (PMN). Frinlender (2013) points
out an anti-tumor phenotype of TANs. Of particular interest is
the study of interaction of neutrophils with T cells because the
latter are considered to be cytotoxic cells mediating antitumor
immunity. The aim of the study was to assess the lymphoid cell
infiltration (LCI) and the functional status of TANs in ovarian
cancer. LCI was assessed by immunohistochemistry and the
levels of mieloproxydase (MPO) and cationic proteins (CP) were
evaluated by cytochemical methods in ovarian carcinoma surgi-
cal resection specimens. The results were presented as a mean
cytochemical coefficient (MCC). The intensity of nitroblue
tetrazolium (NBT) test was expressed as a percentage. Obtained
results were analyzed by nonparametric statistical methods.
The Kruskal–Wallis test was used to evaluate the differences
between groups.
We established that low intensity of infiltration in general and
formation of marginal lymphoid cell ridge in some tumors are
typical for malignant ovarian neoplasms. More intensive infiltra-
tion was found in the regions of the rapid growth of tumor cells,
i.e. invasion zone. In some cases, a group of tumor cells was sep-
arated from the main part of the parenchyma and surrounded by
lymphoid elements. Conditions are created under which active
spread of cancer cells in the parenchyma is associated with inten-
sive lymphoid cells infiltration in the stroma. Total count and
density of lymphoid cells can significantly vary: from single
lymphoid elements uniformly scattered in the tumor tissue to
focal accumulations. In tumor tissue location of lymphoid cells
is irregular, so most of the infiltration is in the stroma and among
the cancer cells only solitary lymphocytes are found. Lymphoid
cells which make up the infiltration include 12.3 ± 1.52% of
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